text.skipToContent text.skipToNavigation

Analyst Research

Sartorius Stedim Biotech is currently covered by eight sell-side analysts. The following list shows their latest recommendation for the Sartorius Stedim Biotech share.

Institution Analyst Date Target Price Recommendation
AlphaValue Kamla Singh 25.10.2018 79.80 Sell
Société Générale Patrick Jousseaume 24.10.2018 105.00 Hold
Oddo Midcap Christophe-Raphael Ganet 23.10.2018 90.00 Hold
Gilbert Dupont Guillaume Cuvillier 09.10.2018 97.00 Sell
Janney Paul Knight 03.10.2018 121.00 Hold
UBS Michael Leuchten 07.08.2018 115.00 Buy
Equita Gianmarco Bonacina 03.04.2018 80.00 Hold
Portzamparc Geoffroy Michalet 06.03.2017 58.00 Hold


Based on an internal database, we have assigned the recommendations indicated below to buy, hold and sell categories. This list does not claim to be exhaustive.

Buy     Buy | Outperform | Overweight

Hold   Hold | Neutral

Sell     Sell | Underperform | Underweight


The analysts’ estimates listed above as examples are not based on research or analyses conducted by Sartorius AG, but rather exclusively on analyses, research, reports, recommendations or ratings of third parties. References to such recommendations and ratings are provided as convenience for readers and for non-binding informational purposes only. These references do not imply that Sartorius AG adopts, endorses or confirms in any way the recommendations, options, opinions, conclusions or estimates of analysts. In particular, analysts’ estimates do not constitute any investment advice given by Sartorius AG. None of the information provided is intended as an offer or encouragement to buy Sartorius shares or other financial instruments, nor is it an offer to purchase or sell.

Sartorius AG shall not assume any liability, in particular for the selection, topicality, quality, completeness or accuracy of the analysts’ estimates shown and, if any, of analysts’ recommendations. Any liability on the part of Sartorius AG for damages or losses incurred by third parties based on the information published on this website shall be excluded.